In a dose-finding, clinical trial, Terkeltaub et al. examined the safety and efficacy of tigulixostat, a nonpurine xanthine oxidase inhibitor, for lowering the serum urate levels of patients with gout and hyperuricemia.
![](https://www.the-rheumatologist.org/wp-content/uploads/2022/02/gout-abstracts-art-150x150.png)
Research Roundup: Abstract Data Presented at ACR Convergence 2021
The research presented at ACR Convergence 2021 had a broad scope. Below are details on three studies that addressed cardiovascular safety in treat-to-target strategies, phase 2 study results on the efficacy of tigulixostat and the impact of patient preference on treatment adherence. Take our quiz after you read this article. Treat to Target Abstract L06:…
![](https://www.the-rheumatologist.org/wp-content/uploads/2017/02/Generic_shutterstock_DrugsPills_500x270-150x150.jpg)
Tigulixostat Appears Promising for the Treatment of Gout
In a phase 2 study, tigulixostat treatment proved safe for lowering serum uric acid (sUA) levels in patients with gout.